Patents Assigned to Calitor Sciences, LLC
-
Publication number: 20170073334Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: September 7, 2016Publication date: March 16, 2017Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Minxiong Li, Xiaobo Li, Wuhong Chen, Tao Zhang, Haiyang Hu, Weilong Dai, Yanjun Wu
-
Patent number: 9573953Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: GrantFiled: February 15, 2014Date of Patent: February 21, 2017Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventor: Ning Xi
-
Patent number: 9518046Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.Type: GrantFiled: March 15, 2015Date of Patent: December 13, 2016Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Liang Wang, Zuping Wu, Xuejin Feng, Yanjun Wu
-
Patent number: 9512114Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.Type: GrantFiled: March 15, 2015Date of Patent: December 6, 2016Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Liang Wang, Tingjin Wang
-
Publication number: 20160318913Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.Type: ApplicationFiled: March 15, 2015Publication date: November 3, 2016Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLCInventors: Ning Xi, Liang Wang, Zuping Wu, Xuejin Feng, Yanjun Wu
-
Publication number: 20160318914Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.Type: ApplicationFiled: March 15, 2015Publication date: November 3, 2016Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.Inventors: Ning Xi, Liang Wang, Tingjin Wang
-
Publication number: 20160229837Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: October 10, 2015Publication date: August 11, 2016Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLCInventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Haiyang Hu, Tao Zhang, Wuhong Chen
-
Patent number: 9403801Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: March 27, 2015Date of Patent: August 2, 2016Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Haiyang Hu, Weilong Dai
-
Patent number: 9399637Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: March 27, 2015Date of Patent: July 26, 2016Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Tao Zhang, Yanjun Wu
-
Patent number: 9399639Abstract: The present invention provides substituted azaindole prodrugs, methods of making said prodrugs, pharmaceutical compositions of said prodrugs and methods of using said prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer.Type: GrantFiled: August 26, 2013Date of Patent: July 26, 2016Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Tingjin Wang, Yin Tang, Mingming Sun, Qian Wang
-
Patent number: 9394281Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: GrantFiled: March 27, 2015Date of Patent: July 19, 2016Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Tingjin Wang
-
Patent number: 9326975Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: GrantFiled: January 20, 2015Date of Patent: May 3, 2016Assignees: SUNSHINE LAKE PHARMA CO., LTD, CALITOR SCIENCES, LLCInventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
-
Publication number: 20150342945Abstract: The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: August 12, 2015Publication date: December 3, 2015Applicants: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventor: Ning XI
-
Publication number: 20150299219Abstract: The present invention provides substituted bicyclic pyrazolone compounds, which are used to inhibit or modulate the activity of receptor tyrosine kinases, especially Axl, Mer, c-Met and Ron. The invention also provides pharmaceutical compositions comprising the compound disclosed herein, and a method of preventing, treating or lessening the severity of a proliferative disorder in a patient with the compounds or the pharmaceutical compositions disclosed herein.Type: ApplicationFiled: April 16, 2015Publication date: October 22, 2015Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.Inventors: Ning Xi, Yanjun Wu
-
Publication number: 20150274747Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: March 27, 2015Publication date: October 1, 2015Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Tingjin Wang
-
Publication number: 20150274705Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: March 27, 2015Publication date: October 1, 2015Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLCInventors: Ning Xi, Minxiong Li, Xiaobo Li, Tao Zhang, Yanjun Wu
-
Publication number: 20150274704Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.Type: ApplicationFiled: March 27, 2015Publication date: October 1, 2015Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLCInventors: Ning Xi, Minxiong Li, Haiyang Hu, Weilong Dai
-
Patent number: 9133162Abstract: The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: GrantFiled: February 21, 2012Date of Patent: September 15, 2015Assignees: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLCInventor: Ning Xi
-
Publication number: 20150141463Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: January 20, 2015Publication date: May 21, 2015Applicants: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
-
Publication number: 20150087658Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.Type: ApplicationFiled: September 17, 2014Publication date: March 26, 2015Applicants: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.Inventors: Ning Xi, Liang Wang, Tingjin Wang